BRKR vs TXG: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
BRKR is the larger of the two ($9.57B market cap): the incumbent the market prices for continued execution (25.87x forward earnings, beta 1.29). TXG is the smaller challenger ($6.00B), actually pricier on forward earnings (228.72x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
BRKR vs TXG: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BRKR | TXG | What it tells you |
|---|---|---|---|
| Market cap | $9.57B | $6.00B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 25.87 | 228.72 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.29 | 2.04 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 93% of range | 92% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 3.91 | 7.49 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: BRKR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how BRKR and TXG affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BRKR and TXG share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BRKR and TXG exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Bruker Corporation (BRKR) do?
Bruker Corporation designs and sells high-performance scientific instruments used in research, life sciences, materials science, and industrial applications. It operates through four segments: BioSpin (nuclear magnetic resonance spectroscopy and preclinical imaging), CALID (mass spectrometry and chromatography for life-science and applied markets), Nano (surface analysis and microscopy including atomic force microscopy), and BEST (superconducting magnets and X-ray detectors). The company is a recognized leader in specialized, complex applications such as structural biology, proteomics, and advanced materials, competing in what is effectively a duopoly with Thermo Fisher in high-end NMR and mass spectrometry.
What does 10x Genomics (TXG) do?
10x Genomics, Inc. (Nasdaq: TXG) builds instruments, reagents, and software for single-cell and spatial biology, the tools scientists use to read gene activity one cell at a time and map it across intact tissue. Its core franchises are Chromium (single-cell analysis), the Visium and Xenium spatial platforms, and the newly launched Atera in situ system (list price around $495,000, shipping in the second half of 2026). Revenue skews toward recurring consumables sold to academic labs, pharma and biotech research groups, and core genomics facilities, with instrument placements driving the razor-and-blade model over time.
BRKR vs TXG: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- BRKR drivers: High-end instruments moat; Adjacent growth vectors.
- TXG drivers: Consumables-led recurring revenue; New platform launches (Atera and spatial).
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Bruker's largest customers are academic, government, and pharmaceutical research labs, so cuts to U.S. For TXG, the biggest overhang is demand: U.S.
BRKR or TXG: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BRKR if you believe its drivers more; TXG if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BRKR and TXG guides.
BRKR vs TXG: the full fundamentals
BRKR. Bruker beat reduced Q1 2026 expectations (non-GAAP EPS of ~$0.31 versus a ~$0.23 consensus) even as organic revenue fell, and it reaffirmed full-year guidance. The forward earnings multiple of roughly 15x to 16x reflects the market weighing a quality niche franchise against near-term research-spending softness.
TXG. 10x Genomics trades at roughly 7x sales while revenue is essentially flat and the company still runs a small net loss, so the market is paying for future growth rather than current profits. The debt-free balance sheet with about $540M of cash gives it room to fund new launches. The key swing factor is whether academic and biopharma spending thaws enough to restart instrument placements.
Headline figures (approximate, July 2026): BRKR shows revenue (ttm) ~$3.46B, q1 2026 revenue ~$823M (+2.7% YoY, -4.4% organic), fy2026 revenue guidance ~$3.57B to $3.60B, fy2026 non-gaap eps guidance ~$2.10 to $2.15; TXG shows revenue (ttm) ~$639M, q1 2026 revenue ~$150.8M, 2026 revenue guidance ~$600M-$625M, gross margin ~70%.
The bottom line: BRKR vs TXG
BRKR and TXG are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BRKR and TXG exposure against your real portfolio. It is not an investment adviser.
Wondering how BRKR or TXG fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Bruker Corporation with AI
Connect the broker you already use and ask Walnut's AI how BRKR fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between BRKR and TXG?
+
Bruker Corporation designs and sells high-performance scientific instruments used in research, life sciences, materials science, and industrial applications. 10x Genomics, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BRKR or TXG the better stock?
+
Neither is universally better. BRKR is the larger incumbent; TXG is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BRKR or TXG?
+
On forward P/E (as of August 2026), BRKR trades at 25.87x and TXG at 228.72x, so BRKR is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BRKR and TXG?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BRKR vs TXG?
+
BRKR: Bruker's largest customers are academic, government, and pharmaceutical research labs, so cuts to U.S. and international research funding directly pressure demand, and organic revenue has been declining as a result. The company flagged an approximately $100 million revenue headwind and $90 million operating-profit impact tied to academic funding disruptions. Heavy acquisition activity introduces integration risk and can mask organic softness, while a large, more diversified competitor in Thermo Fisher can outspend Bruker across the portfolio. Supply-chain exposure to items like high-performance memory chips and liquid helium, plus U.S.-China trade and geopolitical tensions, add further uncertainty. Turning frontier technologies into repeatable, high-volume commercial revenue remains an ongoing execution challenge. TXG: The biggest overhang is demand: U.S. academic and NIH-linked research funding plus biopharma capital budgets have tightened sharply, and instrument sales dropped about 24% year over year, driving management's flat guidance. The company is still unprofitable on a net basis, so the valuation (price-to-sales near 7x) leans heavily on a growth reacceleration that may not arrive on schedule. Competition is intensifying from Illumina, Bruker Spatial, Bio-Techne, Akoya, Vizgen, Bio-Rad, and newer single-cell entrants, and 10x has a long history of patent litigation whose settlements produced non-recurring revenue that will not repeat. New-platform adoption (Atera) is unproven at scale, and results can be lumpy quarter to quarter.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BRKR or TXG; figures are approximate and dated (as of August 2026). Verify current data before investing.